



The Role of COX-2 in Knee Osteoarthritis: A Comprehensive Analysis of Cytokines, Inflammation and Signaling Pathways

You Zhou^{*}, Chaoxin Liang

Department of Medicine, Guangxi Orthopedic Hospital, Nanning, People's Republic of China

ABSTRACT

Knee Osteoarthritis (KOA) of the knee is a prevalent joint disorder closely associated with multiple factors, among which Cyclooxygenase-2 (COX-2) plays an important role in inflammatory responses and cytokine release. This review aims to elucidate the role of COX-2 in the pathogenesis of knee osteoarthritis, analyze its interplay with key cytokines and examine the signaling pathways involved in this process. By employing immunohistochemical techniques, we intend to gain a deeper understanding of the expression patterns of COX-2 and its functions within the inflammatory microenvironment, thereby providing new insights for the treatment of knee osteoarthritis.

Keywords: COX-2; Knee osteoarthritis; Cytokines; Inflammation; Signal transduction; Immunohistochemistry

INTRODUCTION

Knee Osteoarthritis (KOA) is a prevalent degenerative joint disease characterized by the progressive deterioration of articular cartilage, subchondral bone remodelling and synovial inflammation. Epidemiological studies indicate that KOA affects approximately 10% of men and 18% of women over the age of 60 globally, with a significant burden observed in the Middle East and North Africa (MENA) region, where the prevalence has increased markedly from 1990 to 2019 [1]. Clinically, KOA presents with symptoms such as joint pain, stiffness, swelling and decreased range of motion, significantly impairing the quality of life and functional capacity of affected individuals [2]. The disease's multifactorial nature, influenced by age, obesity, joint injury and genetic predisposition, necessitates comprehensive understanding and management approaches [3].

Cyclooxygenase-2 (COX-2) is an enzyme that plays an essential role in the inflammatory response and pain pathways. It is induced during inflammatory processes and is responsible for the conversion of arachidonic acid into prostaglandins, which mediate inflammation and pain [4]. In the context of KOA, elevated COX-2 expression has been associated with increased levels of inflammatory cytokines, contributing to the synovial inflammation characteristic of the disease [5]. This highlights the potential of COX-2 as a therapeutic target, as selective COX-2 inhibitors have been shown to alleviate pain and improve function in KOA patients [6].

Cytokines, particularly pro-inflammatory cytokines such as interleukins (IL-1 β , IL-6) and Tumor Necrosis Factor-alpha (TNF- α),

play an important role in the pathophysiology of KOA. These cytokines are involved in the inflammatory cascade that leads to cartilage degradation and synovial inflammation. The infrapatellar fat pad, a significant source of inflammatory cytokines, contributes to the local inflammatory environment in KOA, further exacerbating joint damage [7,8]. Understanding the interaction between COX-2 and cytokines in KOA is essential for developing targeted therapies aimed at mitigating inflammation and preserving joint function.

LITERATURE REVIEW

The objective of this review is to elucidate the epidemiology and clinical manifestations of KOA, examine the biological functions of COX-2 in inflammation and explore the important role of cytokines in the disease's progression. By synthesizing current literature, this review aims to highlight potential therapeutic avenues and inform clinical practice in managing KOA effectively.

The relationship between COX-2 and KOA

COX-2 is a key enzyme involved in the inflammatory process and is significantly upregulated in osteoarthritis (OA). The expression of COX-2 is primarily regulated by various pro-inflammatory cytokines, such as Interleukin-1 (IL-1) and TNF- α , which are often elevated in OA.

The expression of COX-2 and its regulatory mechanisms: Studies have shown that the activation of signaling pathways, including NF- κ B and MAPK, plays an essential role in inducing COX-2 expression

Correspondence to: You Zhou, Department of Medicine, Guangxi Orthopedic Hospital, Nanning, People's Republic of China, E-mail: 969398318@qq.com

Received: 23-Oct-2024, Manuscript No. BLM-24-27239; **Editor assigned:** 25-Oct-2024, PreQC No. BLM-24-27239 (PQ); **Reviewed:** 08-Nov-2024, QC No. BLM-24-27239; **Revised:** 15-Nov-2024, Manuscript No. BLM-24-27239 (R); **Published:** 22-Nov-2024, DOI: 10.35248/0974-8369.24.16.751

Citation: Zhou Y, Liang C (2024). The Role of COX-2 in Knee Osteoarthritis: A Comprehensive Analysis of Cytokines, Inflammation and Signaling Pathways. *Bio Med.* 16:751.

Copyright: © 2024 Zhou Y, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

in chondrocytes and synovial cells under inflammatory conditions. For instance, the aberrant expression of COX-2 correlates with the downregulation of microRNA-758-3p in synovial tissues of OA patients, indicating a complex regulatory network involving both transcriptional and post-transcriptional mechanisms [9]. Additionally, the role of oxidative stress in modulating COX-2 expression has been highlighted, where Reactive Oxygen Species (ROS) can activate transcription factors that enhance COX-2 gene expression [10]. Understanding these regulatory mechanisms is essential for developing targeted therapies aimed at reducing COX-2 levels and reducing inflammation in OA.

The pathological role of COX-2 in osteoarthritis: The pathological role of COX-2 in KOA is multifaceted, primarily contributing to inflammation, cartilage degradation and pain. Elevated COX-2 levels are associated with increased production of prostaglandins, which are mediators of pain and inflammation in OA [11]. The persistent expression of COX-2 in the joint leads to a vicious cycle of inflammation and cartilage destruction, exacerbating the disease progression. Moreover, selective COX-2 inhibitors have been shown to possess chondroprotective effects, suggesting that managing COX-2 activity could be a viable therapeutic strategy [12]. Research indicates that COX-2 not only influences inflammatory pathways but also interacts with other signaling molecules that contribute to chondrocyte apoptosis and extracellular matrix degradation. Therefore, targeting COX-2 could potentially halt or reverse the degenerative processes associated with KOA.

The role of cytokines in KOA

Cytokines are pivotal in the pathophysiology of knee osteoarthritis, with both pro-inflammatory and anti-inflammatory cytokines playing significant roles. Major pro-inflammatory cytokines involved in OA include IL-1, TNF- α and IL-6, which are known to promote inflammation, cartilage degradation and pain [5].

Classification and function of major cytokines: These cytokines act by stimulating the production of Matrix Metalloproteinases (MMPs) and inhibiting the synthesis of cartilage matrix components, leading to the destruction of articular cartilage. Conversely, anti-inflammatory cytokines, such as IL-10 and Transforming Growth Factor Beta (TGF- β), are essential for maintaining cartilage homeostasis and promoting repair mechanisms [8]. The balance between these cytokines is essential for joint health and dysregulation can lead to the progression of OA.

The interaction between cytokines and COX-2: The interaction between cytokines and COX-2 is an essential aspect of the inflammatory response in knee osteoarthritis. Pro-inflammatory cytokines, particularly IL-1 and TNF- α , have been shown to upregulate COX-2 expression in chondrocytes, thereby enhancing the production of inflammatory mediators such as prostaglandins [13]. This positive feedback loop amplifies the inflammatory response and contributes to the symptoms of OA. Furthermore, studies suggest that the interplay between cytokines and COX-2 can influence chondrocyte survival and apoptosis, affecting cartilage integrity [14]. Understanding these interactions provides insights into potential therapeutic targets, as modulating the effects of specific cytokines or inhibiting COX-2 could help alleviate inflammation and slow the progression of osteoarthritis.

Mechanisms of inflammatory response in knee osteoarthritis

The inflammatory response in KOA is a complex process that involves the activation of various immune cells and the release of pro-inflammatory cytokines. This process is initiated by mechanical

stress and damage to the cartilage, which leads to the release of Damage-Associated Molecular Patterns (DAMPs) that activate Pattern Recognition Receptors (PRRs) on synovial cells and immune cells within the joint.

Initiation and Maintenance of Inflammation: The activation of these receptors triggers a cascade of inflammatory signaling pathways, including the Nuclear Factor Kappa-Light-Chain-enhancer of activated B cells (NF- κ B) pathway, which plays an essential role in the transcription of pro-inflammatory cytokines such as IL-1 and TNF- α [15].

Moreover, the maintenance of inflammation in knee OA is sustained by the continuous presence of inflammatory mediators and the recruitment of additional immune cells, such as macrophages and T cells, to the joint. These cells not only produce inflammatory cytokines but also secrete MMPs that contribute to cartilage degradation [16]. Recent studies have highlighted the role of galectin-3 in promoting synovial inflammation through the activation of the phosphatidylinositol-3-kinase/Akt pathway, indicating a potential therapeutic target for managing inflammation in OA [17]. Additionally, the presence of chronic inflammation in the synovial fluid of OA patients has been associated with the severity of the disease, further emphasizing the need for effective anti-inflammatory strategies [18].

Role of COX-2 in the inflammatory response: COX-2 is a key enzyme involved in the inflammatory response in knee osteoarthritis, primarily responsible for the conversion of arachidonic acid into prostaglandins, which are potent mediators of inflammation. Elevated levels of COX-2 have been observed in the synovial tissue and fluid of OA patients, correlating with increased levels of Prostaglandin E₂ (PGE₂), a pro-inflammatory mediator that exacerbates pain and inflammation in the joint [4]. The inhibition of COX-2 has been shown to reduce the levels of inflammatory cytokines and alleviate symptoms in OA patients, making it a target for therapeutic intervention [19].

Moreover, recent research has indicated that COX-2 not only contributes to the inflammatory process but also plays a role in the resolution of inflammation. Specialized pro-resolving mediators derived from omega-3 fatty acids can modulate COX-2 activity, promoting the resolution of inflammation and restoring tissue homeostasis [20]. The dual role of COX-2 in both promoting and resolving inflammation highlights the complexity of targeting this enzyme in therapeutic strategies. Inhibition of COX-2 has been associated with adverse effects, including gastrointestinal complications, necessitating a careful consideration of the therapeutic approaches used in managing KOA [21]. Understanding the precise mechanisms by which COX-2 influences inflammation in KOA will be essential for developing effective treatments that balance pain relief and inflammation resolution.

The role of signal transduction pathways in COX-2 regulation

Signal transduction pathways are essential for cellular communication and play a significant role in regulating various biological processes, including inflammation and cancer progression.

Overview of major signal transduction pathways: The primary pathways involved in the regulation of COX-2 include the Mitogen-Activated Protein Kinase (MAPK) pathway, Phosphoinositide 3-kinase (PI3K)/Akt pathway and NF- κ B signaling. The MAPK pathway, which consists of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and p38 MAPK, is activated by various

extracellular stimuli and is involved in regulating gene expression, cell proliferation and apoptosis. The PI3K/Akt pathway is essential for cell survival and growth and its activation leads to the upregulation of COX-2 expression in response to inflammatory signals. NF- κ B is a transcription factor that, when activated, translocates to the nucleus to promote the transcription of pro-inflammatory genes, including COX-2. The interplay among these pathways is complex and their dysregulation can lead to pathological conditions such as cancer and chronic inflammation [22-24].

Interaction between signal transduction pathways and COX-2:

Interaction between signal transduction pathways and COX-2 is important in mediating inflammatory responses and tumorigenesis. For instance, TNF- α , a pro-inflammatory cytokine, activates the NF- κ B pathway, leading to increased COX-2 expression in various cell types, including macrophages and epithelial cells [25,26]. Additionally, studies have shown that the PI3K/Akt pathway can enhance COX-2 expression by promoting the stability of COX-2 mRNA and increasing its translation [27]. Furthermore, the activation of the MAPK pathway, particularly ERK has been implicated in the upregulation of COX-2 during inflammatory responses, indicating a multifaceted regulatory mechanism [28,29]. In cancer, COX-2 is often over expressed and its regulation by these signalling pathways contributes to tumor progression and resistance to apoptosis. Targeting these pathways may provide therapeutic strategies for conditions characterized by elevated COX-2 levels, such as colorectal cancer and other malignancies [30,31]. Understanding the intricate relationship between COX-2 and signal transduction pathways is essential for developing novel anti-inflammatory and anticancer therapies.

DISCUSSION

Applications

Immunohistochemistry is used in many research applications. Immunohistochemistry (IHC) is an essential technique in biomedical research and clinical diagnostics, leveraging the specificity of antibodies to detect particular antigens in tissue sections. Some of the applications are given below.

Basic principles of immunohistochemistry: The fundamental principle of IHC involves the binding of an antibody to its target antigen, followed by visualization through various detection systems, which can be chromogenic or fluorescent. This process typically begins with the fixation of tissue samples to preserve cellular structures, followed by embedding in paraffin or freezing for cryosectioning. The antibodies used in IHC can be monoclonal or polyclonal, each with unique advantages depending on the specificity and sensitivity required for the study. The use of secondary antibodies conjugated to enzymes or fluorophores enhances the detection signal, allowing for the visualization of antigen distribution and expression levels within the tissue microenvironment. Recent advancements have introduced multiplexed IHC techniques, enabling the simultaneous detection of multiple antigens in a single tissue section, which is particularly beneficial for understanding complex biological processes and cellular interactions *in situ* [32,33]. Furthermore, the integration of imaging technologies with IHC has opened new avenues for tissue analysis, providing high-dimensional data that can elucidate the spatial organization and heterogeneity of cellular populations within tissues [34,35].

Applications of immunohistochemistry in KOA research: In the context of KOA, immunohistochemistry has emerged as a powerful

tool for elucidating the pathophysiological mechanisms underlying this degenerative joint disease. IHC allows researchers to visualize and quantify the expression of various biomarkers associated with inflammation, cartilage degradation and bone remodeling in affected tissues. For example, studies have utilized IHC to investigate the localization and expression levels of pro-inflammatory cytokines, MMPs and other mediators involved in the OA process [36,37]. By employing Immunohistochemistry (IHC) techniques, researchers have been able to identify specific cellular populations, such as macrophages and T-cells that contribute to the inflammatory milieu in OA-affected joints [38]. Additionally, the application of multiplex IHC in OA research has facilitated the simultaneous assessment of multiple markers, providing insights into the interaction between different cellular pathways and their contributions to disease progression [39,40]. This comprehensive approach not only enhances the understanding of OA pathogenesis but also aids in the identification of potential therapeutic targets and biomarkers for disease monitoring and progression [41,42]. Overall, the use of immunohistochemistry in KOA research shows its significance in advancing our knowledge of this complex condition and improving clinical outcomes for patients.

The immunohistochemical expression of COX-2 in rat KOA: To determine the immunohistochemical expression of COX-2 in KOA, 30 male SD rats aged 8.5 weeks were selected from the Animal Experiment Center of Guizhou Medical University. The experimental group (10 rats) underwent surgical intervention. Twenty SD male rats were anesthetized with 10% chloral hydrate (3 ml/kg) *via* intraperitoneal injection and once satisfactory anesthesia was achieved, the rats were placed in a supine position and fixed to the surgical table, followed by routine disinfection and draping. The skin of the left and right hind limbs was shaved with a surgical razor and the hind limbs were cleaned with gauze soaked in new chlorhexidine, followed by disinfection with iodine. In the model group (10 rats), a 2 cm incision was made parallel to the medial collateral ligament at the left and right knees, with the skin, muscle and fascia separated in sequence, the joint capsule incised and the patella displaced at a 90° flexion to open the joint cavity. The anterior cruciate ligament was located and cut with scissors and a drawer test was performed to ensure complete transection of the anterior cruciate ligament. The joint cavity was flushed with 0.9% sodium chloride solution and the joint capsule and skin were sutured. In the sham group (10 rats), only the joint capsule was incised without any further treatment and then sutured. After all rats recovered, they were returned to their cages. One month later, the articular cartilage tissues from each group of rats were dewaxed and activated for enzyme assays, followed by routine paraffin embedding and sectioning.

Knee joint immunohistochemical staining: The paraffin sections were dewaxed to water, followed by antigen retrieval and placed in a 3% hydrogen peroxide solution for 25 minutes at room temperature in the dark. The slides were washed 3-5 times in PBS (pH 7.4) on a decolorizing shaker, with each wash lasting 5 minutes and then blocked with serum for 30 minutes. After removing the blocking solution, the prepared primary antibody was added to the sections, which were then incubated in a humid box at 4°C for 12 hours. The corresponding secondary antibody was applied at room temperature for 50 minutes. The slides were washed 3 times in PBS, with each wash lasting 5 minutes. DAB chromogenic solution was added and the chromogenic time was controlled under a microscope; a brown-yellow color indicated a positive result, after which the slides were rinsed with running water to stop the reaction. The cell nuclei were stained with hematoxylin, dehydrated and mounted. The expression of COX-2 related antibodies was detected.

In this study, in the control group, COX-2 antibody showed positive expression in immunohistochemical staining (Figure 1).




Figure 1: Design of cropland sites along with precipitation gradients from east to west in Jilin.

CONCLUSION

In conclusion, the role of COX-2 in KOA is a pivotal element that warrants further investigation. COX-2 is not only an enzyme involved in the inflammatory response but also a key player in the pain pathways associated with OA. The modulation of COX-2 activity could potentially provide therapeutic benefits, as evidenced by the varying responses observed in different studies. As such, it is essential to balance the emerging viewpoints surrounding COX-2 inhibitors, considering both their analgesic properties and their potential adverse effects.

The complex relationship between cytokines and the inflammatory response in KOA further complicates the therapeutic landscape. Cytokines such as IL-1 β and TNF- α are known to exacerbate joint inflammation and degrade cartilage. However, there is a growing body of evidence suggesting that the inhibition of specific cytokine pathways may alleviate symptoms and slow disease progression. This highlights the need for a understanding of the inflammatory milieu in OA, as targeting one cytokine may not yield the desired results without considering the broader context of cytokine interactions.

Moreover, the exploration of signalling pathways as potential therapeutic targets presents an exciting avenue for future research. Pathways such as NF- κ B, MAPK and JAK/STAT are integral to the inflammatory process in OA. Identifying specific inhibitors that can selectively modulate these pathways could lead to innovative treatment strategies that minimize side effects while effectively managing symptoms. Looking ahead, future research should focus on the integration of findings from diverse studies to establish a more comprehensive understanding of OA pathology. Multi-target approaches that consider the interplay between COX-2, cytokines and signalling pathways could enhance therapeutic outcomes.

DECLARATIONS

Ethics committee consent

This paper and accompanying images have been published with the consent of the Hospital and Animal Ethics.

Consent for publication

The publication of this paper has been approved by Guangxi

Orthopedic Hospital.

Availability of data and materials

The data and materials are authentic and available.

Authors' contributions

Both the authors took the responsibility of study concept/design, data collection, writing the paper and essential revision

Acknowledgements

Our sincere regards to Guangxi Orthopaedic Hospital.

Authors' information

Guangxi Bone and Injury Hospital, limb trauma Department, department director, deputy chief physician.

REFERENCES

- Hoveidaei AH, Namini-Ansari A, Chalian M, Roshanshad A, Khonji MS, Masghadiagh A, et al. Burden of knee osteoarthritis in the Middle East and North Africa (MENA): An epidemiological analysis from 1990 to 2019. *Arch Orthop Trauma Surg.* 2023;143(10):6323-6333.
- Spirnals C, Marbouris P, Vaes B, Smeets M, Luyten F, Hermens R, et al. Epidemiology of knee osteoarthritis in general practice: A registry-based study. *BMJ Open.* 2020;10(1):031734.
- Driban JB, Harkey MS, Barbe MF, McAlindon TE, Lu B, Eaton CB, et al. Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review. *BMC Musculoskelet Disord.* 2020;21(1):332.
- Ahmadi M, Bekeschus S, Weltmann KD, von Woedtke T, Wende K. Non-steroidal anti-inflammatory drugs: Recent advances in the use of synthetic COX-2 inhibitors. *RSC Med Chem.* 2022;13(5):471-496.
- Fischer AG, Titchenal MR, Migliore E, Asay JL, Erhart-Hledik JC, Andriacchi TP. Elevated proinflammatory cytokines in response to mechanical stimulus are associated with reduced knee loading 2 years after anterior cruciate ligament reconstruction. *Clin Biomech.* 2024;116:106286.
- Clark GP. Treatment options for symptomatic knee osteoarthritis in adults. *JAAPA.* 2023;36(11):1-6.
- Bafrani HH, Ahmadi M, Jahantigh D, Karimian M. Association analysis of the common varieties of IL17A and IL17F genes with the risk of knee osteoarthritis. *J Cell Biochem.* 2019;120(10):18020-18030.
- Zhou S, Maleitzke T, Geissler S, Hildebrandt A, Fleckenstein FN, Niemann M, et al. Source and hub of inflammation: The infrapatellar fat pad and its interactions with articular tissues during knee osteoarthritis. *J Orthop Res.* 2022;40(7):1492-1504.
- Liu Z, Sun J, Liang T, Huang X. Increased expression of cyclooxygenase-2 in synovium tissues and synovial fluid from patients with knee osteoarthritis is associated with downregulated microRNA-758-3p expression. *Exp Ther Med.* 2021;22(3):1001.
- Ke C, Li H, Yang D, Ying H, Zhu H, Wang J, et al. Melatonin attenuates the progression of osteoarthritis in rats by inhibiting inflammation and related oxidative stress on the surface of knee cartilage. *Orthop Surg.* 2022;14(9):2230-2237.
- Cho SK, Choi S, Kim H, Song YJ, Jung SY, Jang EJ, et al. COX-2 Inhibitor use as an early treatment option for knee osteoarthritis patients in Korea: A population-based cross-sectional study. *J Korean Med Sci.* 2022;37(18):148.
- Timur UT, Caron MMJ, Jeuken RM, Bastiaansen-Jenniskens YM, Welting TJ, van Rhijn LW, et al. Chondroprotective actions of

- selective Cox-2 inhibitors *in vivo*: A systematic review. *Int J Mol Sci*. 2020;21(18):6962.
13. Li W, Hu S, Chen X, Shi J. The antioxidant resveratrol protects against chondrocyte apoptosis by regulating the *cox-2/nf- κ b* pathway in created temporomandibular osteoarthritis. *Biomed Res Int*. 2021;2021:9978651.
 14. Zhao X, Zhang Q, Bu Z. Study on the protective effect of platelet-rich plasma combined with injection of pain points around knee joint on knee osteoarthritis and its molecular mechanism. *Altern Ther Health Med*.
 15. Wang MN, Zhai MX, Wang YT, Dai QF, Liu L, Zhao LP, et al. Mechanism of acupuncture in treating obesity: advances and prospects. *Am J Chin Med*. 2024;52(01):1-33.
 16. Udomsinprasert W, Jittikoon J, Honsawek S. Interleukin-34 as a promising clinical biomarker and therapeutic target for inflammatory arthritis. *Cytokine Growth Factor Rev*. 2019;47:43-53.
 17. Udomsinprasert W, Ungsudechachai T, Wunthong S, Yuttanarad S, Jittikoon J, Honsawek S. Effect of galectin-3 on synovial inflammation in knee osteoarthritis *via* stimulating phosphatidylinositol-3-kinase/Akt pathway. *Int Immunopharmacol*. 2023;122:110673.
 18. Rolle NA, Jan I, Sibbitt WL Jr, Band PA, Haseler LJ, Hayward WA, et al. Extractable synovial fluid in inflammatory and non-inflammatory arthritis of the knee. *Clin Rheumatol*. 2019;38(8):2255-2263.
 19. Liu J, Hou W, Zong Z, Lin X, Zhao H, Tian L, et al. Supplementation of nicotinamide mononucleotide diminishes COX-2 associated inflammatory responses in macrophages by activating kynurenine/AhR signaling. *Free Radic Biol Med*. 2024;214:69-79.
 20. Jordan PM, Werz O. Specialized pro-resolving mediators: Biosynthesis and biological role in bacterial infections. *FEBS J*. 2022;289(14):4212-4227.
 21. Sahu A, Raza K, Pradhan D, Jain AK, Verma S. Cyclooxygenase-2 as a therapeutic target against human breast cancer: A comprehensive review. *WIREs Mech Dis*. 2023;15(3):1596.
 22. Nagaraju GP, El-Rayes BF. Cyclooxygenase-2 in gastrointestinal malignancies. *Cancer*. 2019;125(8):1221-1227.
 23. A Najafi SMA. The canonical wnt signaling (wnt/ β -catenin pathway): A potential target for cancer prevention and therapy. *Iran Biomed J*. 2020;24(5):269-280.
 24. Kontomanolis EN, Koutras A, Fasoulakos G, Sotiropoulos A, Diakosavvas M, Angelou K, et al. A brief overview of oncogenes and signal transduction pathways in gynecological cancer. *Cancer Diagn Progn*. 2022;2(2):134-143.
 25. Hosokawa Y, Hosokawa I, Shimoyama M, Okamoto R, Ozaki K, Hosaka K. The anti-inflammatory effects of iberin on TNF- α -stimulated human oral epithelial cells: *In vitro* research. *Biomedicines*. 2022;10(12):3155.
 26. Okamoto R, Hosokawa Y, Hosokawa I, Ozaki K, Hosaka K. Cardamonin inhibits the expression of inflammatory mediators in TNF- α -stimulated human periodontal ligament cells. *Immunopharmacol Immunotoxicol*. 2024;46(4):521-528.
 27. Eo SH, Kim SJ. Resveratrol-mediated inhibition of cyclooxygenase-2 in melanocytes suppresses melanogenesis through extracellular signal-regulated kinase 1/2 and phosphoinositide 3-kinase/Akt signalling. *Eur J Pharmacol*. 2019;860:172586.
 28. Li B, Wang M, Chen S, Zhu H, He L, Cai J, et al. Baicalin mitigates the neuroinflammation through the TLR4/MyD88/NF- κ B and MAPK pathways in Lps-stimulated BV-2 microglia. *Biomed Res Int*. 2022;2022:3263446.
 29. Jiang R, Zhao S, Wang R, Feng H, Zhang J, Li X, et al. Discovery of phenolic glycoside from *Hyssopus cuspidatus* attenuates Lps-induced inflammatory responses by inhibition of inos and cox-2 expression through suppression of NF- κ B Activation. *Int J Mol Sci*. 2021;22(22):12128.
 30. Han M, Yu H, Yang K, Liu P, Yan H, Yang Z, et al. A network pharmacology-based approach to investigating the mechanisms of fushen granule effects on intestinal barrier injury in chronic renal failure. *Evid Based Complement Alternat Med*. 2021;2021:2097569.
 31. Okamoto R, Hosokawa Y, Hosokawa I, Ozaki K, Hosaka K. Cardamonin decreases inflammatory mediator expression in IL-1 β -stimulated human periodontal ligament cells. *Mol Biol Rep*. 2024;51(1):222.
 32. McGinnis LM, Ibarra-Lopez V, Rost S, Ziai J. Clinical and research applications of multiplexed immunohistochemistry and *in situ* hybridization. *J Pathol*. 2021;254(4):405-417.
 33. Sato K. A case of advanced gastric cancer remarkably responding to preoperative UFT-1 therapy. *Gan to kagaku Ryoho. Cancer and Chemotherapy*. 2021;48(3):320-324.
 34. Marques O, Georgouli M, Sanz-Moreno V. Recent advances in tissue imaging for cancer research. *F1000Res*. 2019;8.
 35. Schlecht A, Boneva S, Salie H, Killmer S, Wolf J, Hajdu RI, et al. Imaging mass cytometry for high-dimensional tissue profiling in the eye. *BMC Ophthalmol*. 2021;21(1):338.
 36. Fang L, Lin L, Lv Y, et al. The mechanism of aerobic exercise combined with glucosamine therapy and circUNK in improving knee osteoarthritis in rabbits. *Life Sci*. 2021;275:119375.
 37. Wang J, Su S, Dong C, Fan Q, Sun J, Liang S, et al. Human adipose-derived stem cells upregulate IGF-1 and alleviate osteoarthritis in a two-stage rabbit osteoarthritis model. *Curr Stem Cell Res Ther*.
 38. Zhang W, Zhang L, Yang S, Wen B, Chen J, Chang J. Electroacupuncture ameliorates knee osteoarthritis in rats *via* inhibiting NLRP3 inflammasome and reducing pyroptosis. *Mol Pain*. 2023;19:17448069221147792.
 39. Shin SM, Cai Y, Itson-Zoske B, Qiu C, Hao X, Xiang H, et al. Enhanced T-type calcium channel 3.2 activity in sensory neurons contributes to neuropathic-like pain of monosodium iodoacetate-induced knee osteoarthritis. *Mol Pain*. 2020;16:1744806920963807.
 40. Chiu PE, Fu Z, Tsai YC, Jian GW, Li TM, Chou LW, et al. Fu's subcutaneous needling promotes axonal regeneration and remyelination by inhibiting inflammation and endoplasmic reticulum stress. *Transl Res*.
 41. Moon SW, Park EH, Park JS, Yoo HJ, Park JH, Kim DS, et al. Pain-relieving effect of 4.4 mhz of pulsed radiofrequency on acute knee arthritis in rats. *Pain Med*. 2020;21(8):1572-1580.
 42. Cheng JH, Wang CJ, Chou WY, Hsu SL, Chen JH, Hsu TC. Comparison efficacy of ESWT and Wharton's jelly mesenchymal stem cell in early osteoarthritis of rat knee. *Am J Transl Res*. 2019;11(2):586-598.